Where does Renibus Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Renibus Therapeutics, Inc. ranks #29,926 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Renibus Therapeutics, Inc. hold?

Renibus Therapeutics, Inc. holds 9 US utility patents granted between 2022 and 2024, spanning 7 technology areas.

What is Renibus Therapeutics, Inc.'s Innovation Score?

Renibus Therapeutics, Inc. has an Innovation Score of 41.9 out of 100 (top 32% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Renibus Therapeutics, Inc. focus on?

Renibus Therapeutics, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 9 patents, ranking #2,395 of 7,163 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Renibus Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Renibus Therapeutics, Inc..

What does claim depth mean for Renibus Therapeutics, Inc.'s patents?

Renibus Therapeutics, Inc.'s patents average 7.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Renibus Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Renibus Therapeutics, Inc.

USPTO PatentsView assignee record - 9 granted patents across 7 technology areas, recorded in grant years 2022–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Renibus ranks #29,926 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 7 technology areas.

#29,926
of 49,997 US assignees by volume: Top 32%
by Innovation Score (41.9/100): 7.7
avg claims per patent

USPTO PatentsView assignee plate

Corpus R29926 · US Corporation #29,926 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-SPARSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 9 grants
MID-PACK #29,926/49,997
PHOTO-FINISH Remington Designs
CPC-NARROW A61K · 7 areas
INNOV-PAR 41.9/100
CLAIMS-SPARSE 7.7 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2022–2024 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Remington Designs, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Renibus’s 41.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.0 pts (19%) Velocity 20.0 pts (48%) Breadth 9.4 pts (22%) Claim depth 4.6 pts (11%)

Qualcomm Incorporated · highest

85
Renibus Therapeutics · this assignee

42
3D Lighting… · lowest

7

What this shows Renibus's Innovation Score is 41.9/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Renibus?

Each dot is one of Renibus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Renibus’s own 7.7 claims/patent is at or below the 13.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Renibus vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Renibus's grants concentrate

Renibus Therapeutics, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2024 (5 grants) versus a trough of 2 in 2022. By volume, Renibus sits between Remington Designs, LLC and Retrace Labs.

Renibus's three-year grant acceleration

Renibus Therapeutics, Inc. shows 9 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Remington Designs

9
Renata Medical

9
Renesas Europe

9
Renewable Edge

9
Rennsteig Werkzeu…

9
Renovo Software

9
Research Cancer I…

9
Retrace Labs

9
Renibus Therapeut… ◀

9

What this shows Renibus holds 9 patents at rank #29,924, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Renibus

By rank, the assignees closest to #29,924 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Renibus's primary technology class.

Renibus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Renibus Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	2	22.2%
2023	2	22.2%
2024	5	55.6%

Which technologies does Renibus Therapeutics, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

A01P - Biocidal, Pest Repellant, Pest Attractant OR Plant Growth Regulatory Activity OF Chemical Compounds OR Preparations 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Renibus Therapeutics, Inc.'s patent record in context - here's where to go next.

Renibus Therapeutics, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #29,926 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Renibus Therapeutics, Inc. against Remington Designs, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.